New cancer vaccine Out

May 3rd, 2010 - 9:46 pm ICT by Pen Men At Work  

May 3, 2010 (Pen Men at Work): The Food and Drug Administration (FDA) of America has supplied its approval to the latest prostate cancer vaccine, Provenge. It has been manufactured by the biotech company, Dendreon, and will lend a hand to the patients to live a little longer. Dendreon first presented its vaccine to the FDA for endorsement in 2006.

The vaccine is produced by revealing patients’ immune cells outside the body to prostate cancer cells. The uncovered immune cells are then inserted into patients with the mission of priming the patients’ immune structure to assault the cancer.

Prostate cancer grows in a gland in the male reproductive system, from where it can disseminate to the bones and lymph nodes. It normally plagues men after 50 years of age and is the second-most frequent cancer after skin.

Currently, prostate cancer is taken care of by utilizing radiation, by surgical procedure to extract the gland, by drugs to diminish the levels of the hormone testosterone that nourishes the tumors, and also by the chemotherapy drug, Taxotere, which lengthens the lives of patients by some months.

The other accepted vaccines for cervical cancer, measles or polio are provided as a precautionary measure. The new cancer vaccine will make a patient’s immune system take care of the cancer by assaulting the tumor.

Dr. V. M. Katoch, secretary of department of health research, has declared that this vaccine has supplied optimism to all the cancer patients. The scientists are now functioning on similar vaccines for cancers of the breast, lung, skin and lymph nodes.

Related Stories

Tags: , , , , , , , , , , , , , , , , , , ,

Posted in Health |

Subscribe